Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
News|Articles|March 1, 2019
GHO Capital Acquires Sterling Pharma Solutions
Author(s)Pharmaceutical Technology Editors
GHO Capital, a European specialist investor in healthcare, announced its acquisition of Sterling Pharma Solutions, which specializes in complex and difficult-to-manufacture APIs.
Advertisement
In a Feb. 28, 2019 press release, GHO Capital, a European specialist investor in healthcare, announced its acquisition of Sterling Pharma Solutions, which specializes in complex and difficult-to-manufacture APIs.
Kevin Cook, CEO of Sterling Pharma Solutions, commented, “We are delighted to partner with GHO Capital, whose expertise in the pharmaceuticals space and track record of supporting companies expand internationally will be invaluable in facilitating the next stage of our growth in Europe and in the United States.”
“Sterling provides a compelling opportunity to partner with a management team to support the global demand for complex chemistry in pharmaceuticals,” added Alan MacKay, partner at GHO Capital. “Sterling is today a leader in Europe from its United Kingdom operations and the plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.”
Sterling is headquartered in Newcastle-upon-Tyne, UK, and offers specialist services in API development and GMP manufacturing in order to support customers throughout the full product lifecycle.
Source:
Advertisement
Related to this article
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement